Olympus Acquires Israeli Medical Device Company Medi-Tate to Drive Global Urology Business Growth

Article content material

～Strategic Acquisition to Increase its BPH Portfolio into In-office Remedy～

TOKYO & HAMBURG, Germany & CENTER VALLEY, Pa. — Olympus Company (”Olympus” – Director, Consultant Govt Officer, President and CEO: Yasuo Takeuchi) introduced right this moment that it has finalized the acquisition of Israeli medical system firm Medi-Tate Ltd. (“Medi-Tate” – CEO: Ido Kilemnik) following the announcement of its choice to train the decision possibility in February, 2021. By way of this acquisition, Olympus expands its enterprise line in providing in-office remedy for benign prostatic hyperplasia (BPH) remedy and solidifies its place as a frontrunner within the area of urological gadgets.

Medi-Tate is a medical system producer engaged within the analysis and improvement, manufacturing, and sale of gadgets for the minimally invasive remedy of BPH. The corporate’s flagship product “iTind” has acquired U.S. FDA de Novo authorization and a European CE mark. With its preliminary Medi-Tate funding, Olympus has had the precise of distribution since November 2018.

Article content material

The incidence of BPH, some of the frequent illnesses in growing older males and the most typical reason behind decrease urinary tract signs (“LUTS”), is predicted to extend as the overall world inhabitants will get older. In accordance with the American Urological Affiliation, BPH is a situation that almost 80% of males will face of their lifetime and that ratio is larger in older ages.^ⅰ Medicine and surgical remedy have been among the many typical remedy choices for BPH, and lately, extra minimally invasive surgical remedy gadgets have come to the market.

Olympus is a market chief offering gadgets for BPH remedy reminiscent of resectoscopes and all kinds of electrodes. By including the non-ablative BPH remedy system iTind, which permits sufferers to take care of their sexual operate, to its portfolio, Olympus can present urologists extra remedy choices in line with the signs and wishes of their sufferers, starting from in-offices day remedy to surgical therapies in hospitals.

Nacho Abia, Chief Working Officer of Olympus Company, stated, “the acquisition of Medi-Tate aligns with our company technique of specializing in three precedence therapeutic areas inside our Therapeutic Options Division — gastroenterological endotherapy gadgets, urological gadgets and respiratory endotherapy gadgets. Medi-Tate’s revolutionary merchandise provide a very minimally invasive remedy possibility for sufferers and adaptability within the supply of take care of healthcare professionals.”

Ido Kilemnik, Chief Govt Officer of Medi-Tate, commented, “We consider Olympus appreciates our deal with long-term medical outcomes and dedication of your entire Medi-Tate crew. We’re happy to be becoming a member of Olympus, which shares our imaginative and prescient of constructing iTind the worldwide normal for BPH remedy. We’re excited to be collaborating with Olympus in our effort to reinforce the sufferers’ high quality of life.”

Minimally invasive remedy enabled by iTind

iTind, a quickly implanted nitinol system, helps the reduction of decrease urinary tract signs (LUTS) as a result of BPH. The iTind remedy is carried out by an urologist in an outpatient hospital, ambulatory surgical procedure middle or in a doctor’s workplace, the place the iTind system is positioned within the prostate in a folded configuration. The system slowly expands and exerts mild stress at three exact factors to reshape the prostatic urethra and bladder neck. After 5 to seven days, the system is totally eliminated, leaving a wider opening via which urine can movement for the reduction of BPH signs.

Article content material

i American Urological Affiliation, Benign Prostatic Hyperplasia. Out there at:
https://www.auanet.org/education/auauniversity/medical-student-education/medical-student-curriculum/bph

About Medi-Tate

Medi-Tate is an Israeli medical system firm devoted to bettering males’s healthcare and high quality of life by way of efficient, non-surgical options for Benign Prostatic Hyperplasia (BPH). The flagship iTind remedy for BPH at present has the EU CE Mark and is authorized on the market within the European Union, UK, Israel, Australia, Brazil, and the FDA cleared to be used in the US. For extra info, go to www.medi-tate.com.

AboutOlympus’ Therapeutic Options enterprise

In its Therapeutic Options enterprise, Olympus makes use of revolutionary capabilities in medical expertise, therapeutic intervention, and precision manufacturing to assist healthcare professionals ship diagnostic, therapeutic, and minimally invasive procedures to enhance medical outcomes, cut back general prices, and improve the standard of life for sufferers and their security. Beginning with its early contributions to the event of the polypectomy snare, Olympus’ Therapeutic Options portfolio has grown to incorporate an array of surgical power gadgets and a variety of devices to assist forestall, detect, and deal with illness. For extra info, go to www.olympus-global.com.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20210527005341/en/

Contacts

For questions or further info:

Europe, Center East and Africa
Matthias Gengenbach
+49 15142369420
matthias.gengenbach@olympus-europa.com

United States
Jennifer Bannan
+1 412-403-8742
jennifer.bannan@olympus.com

Japan and APAC
Yuka Horimoto
+81-90-2490-1071
yuka.horimoto@olympus.com